^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

NKG2D CAR T-cells

i
Associations
News
Company:
Shanghai Yake Biotech
Drug class:
NKG2D-targeted CAR-T immunotherapy
Associations
News
Phase 1
Zhejiang University
Not yet recruiting
Last update posted :
12/08/2020
Initiation :
01/15/2021
Primary completion :
01/15/2024
Completion :
01/15/2027
NKG2D
|
NKG2D CAR T-cells